ArticleGeroScience2026
Plasma proteins associated with disability and mortality risks in Japanese community-dwelling octogenarians.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Japan has one of the world's longest life expectancies, yet biomarkers associated with disability and mortality in very old adults remain uncertain. The goal of this study was to identify plasma proteins associated with incident disability and mortality in community-dwelling octogenarians. Two prospective cohorts were analyzed: the Kawasaki Aging Well-being Project (KAWP; 2017-2018; 4.5-year follow-up) as discovery and Invecchiare in Chianti (InCHIANTI; 1998-2000; 15-year follow-up) for external replication. The discovery sample comprised 230 disability-free adults aged 85-89 years (50.4% women). Twenty-nine plasma proteins were assayed using Luminex xMAP. Associations with incident disability and mortality were estimated with elastic net-regularized Cox models and tested in multivariable Cox models in the full KAWP cohort and in InCHIANTI. Higher beta-2-microglobulin and cystatin C levels were associated with an increased risk of disability (hazard ratio [HR] 1.35, 95% confidence interval [CI] 1.11-1.64; HR 1.42, 95% CI 1.14-1.76). For mortality, epidermal growth factor was inversely associated (HR 0.51, 95% CI 0.27-0.96), while interferon gamma-induced protein 10 was positively associated (HR 1.23, 95% CI 1.06-1.44). Associations with disability were broadly replicated in the full KAWP cohort and among InCHIANTI participants aged ≥ 80 years, whereas mortality-related findings were not replicated. In conclusion, beta-2-microglobulin and cystatin C may serve as biomarkers of future disability. These patterns implicate kidney dysfunction and inflammation as drivers of health decline in very old adults and support early risk stratification to guide preventive interventions.
Indexed as
Identifiers
42364072What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.